OPEN ACCESS Freely available online

Molecular Pathology and Biochemistry

Short Communication

Multi-Omics Approaches for Biomarker Identification

Grace Wanjiku *

Department of Clinical Biochemistry, Moi University, Eldoret, Kenya.

ABOVE THE STUDY

The identification of reliable and clinically meaningful biomarkers remains a central challenge in modern biomedical research. In recent years, multi-omics approaches have emerged as a powerful strategy to address this challenge by integrating data from genomics, transcriptomics, proteomics, metabolomics, and epigenomics. In my opinion, the major advantage of multi-omics lies in its ability to capture the complexity of biological systems in a holistic manner, rather than relying on single-layer molecular information that often fails to reflect disease heterogeneity.

Traditional biomarker discovery methods have typically focused on individual molecular classes, such as gene mutations or protein expression levels. While these approaches have yielded important clinical markers, their predictive power is often limited due to the multifactorial nature of most diseases. Multi-omics integration allows researchers to construct a more comprehensive view of disease biology by linking genetic variation with downstream functional changes at protein, and metabolite levels [1].

Genomics provides the foundational blueprint of biological systems by identifying alterations associated with disease susceptibility. However, not all genetic mutations lead to functional consequences. Transcriptomics bridges this gap by revealing gene expression changes, offering insights into active biological processes. Proteomics further refines this understanding by reflecting actual protein abundance and post-translational modifications, while metabolomics captures the end products of cellular activity, providing a real-time snapshot of physiological states [2].

One of the key strengths of multi-omics is its ability to identify convergent biomarker signatures across different molecular layers. For example, a disease-associated gene mutation identified through genomics may also show altered mRNA expression, protein dysregulation, and metabolic pathway disruption. Such convergence increases the robustness and clinical relevance of candidate biomarkers. In my view, this cross-validation across omics layers significantly reduces false-positive findings that are common in single-omics studies [3].

In cancer research, multi-omics approaches have been particularly transformative. Integrated analyses have enabled the classification of tumors into molecular subtypes with distinct prognostic and therapeutic implications. For instance, combining genomic mutations with transcriptomic and proteomic profiles has improved the identification of driver pathways and actionable targets [4]. This has direct implications for precision oncology, where treatment decisions are increasingly based on molecular signatures rather than histopathological features alone.

Neurodegenerative diseases also benefit from multi-omics integration. In conditions such as Alzheimer's disease, combining genomic risk factors with transcriptomic and metabolomic alterations has revealed complex networks involving inflammation, synaptic dysfunction, and energy metabolism [5]. These integrated datasets provide a more comprehensive understanding of disease progression than any single molecular layer alone.

Similarly, in cardiovascular diseases, multi-omics studies have identified interconnected pathways involving lipid metabolism, inflammation, and oxidative stress. By integrating proteomic and metabolomic data with clinical phenotypes, researchers have been able to identify novel biomarkers for early disease detection and risk stratification [6].

Despite its advantages, multi-omics integration presents significant analytical and computational challenges. One major issue is data heterogeneity, as different omics platforms generate data with varying scales, formats, and noise levels. Effective integration requires advanced bioinformatics tools and statistical frameworks capable of harmonizing these datasets [7]. Machine learning and artificial intelligence are increasingly being employed to address this challenge, enabling pattern recognition across complex biological networks.

Another challenge is sample availability and cost. Generating multi-omics datasets requires multiple assays from the same biological sample, which may not always be feasible, particularly

Correspondence to Grace Wanjiku. Department of Clinical Biochemistry, Moi University, Eldoret, Kenya. E-mail: grace.wanjiku@mu.ac.ke

Received: 19-May-2025, Manuscript No. JMPB-25-41760; **Editor assigned:** 21-May-2025, PreQC No. JMPB-25-41760 (PQ); **Reviewed:** 04-Jun-2025, QC No. JMPB-25-41760; **Revised:** 11-Jun-2025, Manuscript No. JMPB-25-41760 (R); **Published:** 18-Jun-2025. DOI: 10.35248/jmpb.25.6.222.

Citation: Wanjiku G (2025 Multi-Omics Approaches for Biomarker Identification. J Mol Pathol Biochem.6:222.

Copyright: © 2025 Wanjiku G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

in clinical settings. Additionally, the high cost of sequencing and mass spectrometry-based technologies limits large-scale application in resource-constrained environments [8].

Standardization is another critical issue. Differences in experimental protocols, data processing pipelines, and analytical methods can lead to inconsistencies across studies. Establishing standardized guidelines for multi-omics data generation and interpretation is essential for clinical translation [9].

Despite these challenges, the future of biomarker discovery is increasingly moving toward integrative omics frameworks. The development of cloud-based bioinformatics platforms and scalable computational models is facilitating large-scale data integration and interpretation. In my opinion, the convergence of multi-omics with systems biology and artificial intelligence will redefine how biomarkers are discovered, validated, and applied in clinical practice.

In conclusion, multi-omics approaches represent a powerful and comprehensive strategy for biomarker identification, offering deeper insights into disease mechanisms and improving diagnostic accuracy. By integrating multiple layers of biological information, these approaches overcome the limitations of single-omics studies and provide a more complete understanding of complex diseases. Continued technological and computational advancements are expected to accelerate their translation into routine clinical diagnostics [10].

REFRENCES

1. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83.
2. Zehra B, Vinod N, BinEshaq S, Aleksandrova I, Tambi R, Faizan M, et al. Multi-Omics Approaches to Cardiovascular Disease: Technological Innovations and Clinical Translation. Am. J. Physiol. Heart Circ. 2026.
3. Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19:299-310.
4. Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016;166:755-765.
5. Yarbro JM, Shrestha HK, Wang Z, Zhang X, Zaman M, Chu M, et al. Proteomic landscape of Alzheimer's disease: Emerging technologies, advances and insights (2021–2025). Mol Neurodegener. 2025;20:83.
6. Dong J, Sun M, Li Y, Xie Z. Multi-Omics approaches in gene therapy for vascular diseases: bridging genomics, transcriptomics, and epigenetics. J Drug Target. 2026;34:169-184.
7. Correa-Aguila R, Alonso-Pupo N, Hernandez-Rodriguez EW. Multi-omics data integration approaches for precision oncology. Mol. Omics. 2022;18:469-479.
8. Demirel HC, Arici MK, Tuncbag N. Computational approaches leveraging integrated connections of multi-omic data toward clinical applications. Mol Omics. 2022;18:7-18.
9. Shahrajabian MH, Sun W. Survey on multi-omics, and multi-omics data analysis, integration and application. Curr. Pharm. Anal. 2023;19:267-281.
10. Huang S, Chaudhary K, Garmire LX. More is better: recent progress in multi-omics data integration. Curr Opin Biotechnol. 2017;48:140-149.